Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments

European Journal of Cancer

Volumn 48, Issue 5, 2012, Pages 662-671

  Korse, Catharina M ^a   Taal, Babs G ^a   Vincent, Andrew ^a   Van Velthuysen, Marie Louise F ^a   Baas, Paul ^a   Buning Kager, Johanna C G M ^a   Linders, Theodora C ^a   Bonfrer, Johannes M G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Chromogranin A; Cytokeratins; MonoTotal; Neuroendocrine tumours; NSE; ProGRP

Indexed keywords

CHROMOGRANIN A; CYTOKERATIN; CYTOKERATIN FRAGMENT; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHROMOGRANIN A; FEMALE; HUMANS; KERATINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; RECOMBINANT PROTEINS; ROC CURVE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84858703328     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.08.012     Document Type: Article

References (39)

1. E. Bajetta, L. Catena, and G. Procopio Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 16 2005 1374 1380 (Pubitemid 41158484)
2. E. Bajetta, L. Ferrari, and A. Martinetti Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors Cancer 86 1999 858 865 (Pubitemid 29399927)
3. V. Barak, H. Goike, K.W. Panaretakis, and R. Einarsson Clinical utility of cytokeratins as tumor markers Clin Biochem 37 2004 529 540 (Pubitemid 38845016)
4. F.T. Bosman, F. Carneiro, R.H. Hruban, and N.D. Theise WHO Classification of the tumours of the digestive system 4th ed. 2010 IARC Press Lyon, France
5. D. Brattstrom, G. Wagenius, and P. Sandstrom Newly developed assay measuring cytokeratins 8, 18 and 19 in serum is correlated to survival and tumor volume in patients with esophageal carcinoma Dis Esophagus 18 2005 298 303 (Pubitemid 43904774)
6. P.G. Chu, and L.M. Weiss Keratin expression in human tissues and neoplasms Histopathology 40 2002 403 439 (Pubitemid 34535443)
7. M. Cimitan, A. Buonadonna, and R. Cannizzaro Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role Ann Oncol 14 2003 1135 1141 (Pubitemid 36950180)
8. W.W. De Herder Biochemistry of neuroendocrine tumours Best Pract Res Clin Endocrinol Metab 21 2007 33 41
9. B. Eriksson, K. Oberg, and M. Stridsberg Tumor markers in neuroendocrine tumors Digestion 62 Suppl 1 2000 33 38 (Pubitemid 30665937)
10. P. Eriksson, D. Brattstrom, and P. Hesselius Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment Neoplasma 53 2006 285 290 (Pubitemid 44109634)
11. L. Giovanella, L. Ceriani, M. Bandera, and S. Garancini Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase Int J Biol Markers 16 2001 50 55 (Pubitemid 32243582)
12. L. Giovanella, S. La Rosa, and L. Ceriani Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings Int J Biol Markers 14 1999 160 166 (Pubitemid 29495746)
13. M. Giusti, M. Sidoti, C. Augeri, C. Rabitti, and F. Minuto Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man Eur J Endocrinol 150 2004 299 303 (Pubitemid 38443779)
14. J.A. Hanley, and B.J. McNeil The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology 143 1982 29 36 (Pubitemid 12142173)
15. G.L. Horowitz, S. Altail, J.C. Boyd, and J. Zakowski Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory. 3rd ed. 2008 Clinical and Laboratory Standards Institute Pennsylvania
16. D.S. Klimstra, I.R. Modlin, D. Coppola, R.V. Lloyd, and S. Suster The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems Pancreas 39 2010 707 712
17. L. Kolby, P. Bernhardt, and C. Sward Chromogranin A as a determinant of midgut carcinoid tumour volume Regul Pept 120 2004 269 273 (Pubitemid 38726216)
18. C.M. Korse, J.M. Bonfrer, N.K. Aaronson, A.A. Hart, and B.G. Taal Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors Neuroendocrinology 89 2009 296 301
19. C.M. Korse, B.G. Taal, and J.M. Bonfrer An elevated progastrinreleasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival Ann Oncol 2011
20. C.M. Korse, B.G. Taal, C.A. de Groot, R.H. Bakker, and J.M. Bonfrer Chromogranin A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor J Clin Oncol 27 2009 4293 4299
21. La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Human Pathol 2011.
22. I.M. Modlin, B.I. Gustafsson, and S.F. Moss Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease Ann Surg Oncol 17 2010 2427 2443
23. R. Molina ProGRP: a new biomarker for small cell lung cancer Eur J Clin Med Oncol 2 2010 1 8
24. R. Molina, E. Alvarez, and A. Aniel-Quiroga Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies Tumour Biol 32 2011 13 22
25. R. Molina, J.M. Auge, and X. Filella Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer Anticancer Res 25 2005 1773 1778 (Pubitemid 40896801)
26. R. Molina, X. Filella, and J.M. Auge Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors Tumour Biol 24 2003 209 218 (Pubitemid 37500571)
27. T. Muley, W. Ebert, and P. Stieber Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay Clin Chem Lab Med 41 2003 95 103 (Pubitemid 36285392)
28. S. Niho, Y. Nishiwaki, and K. Goto Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen Lung cancer 27 2000 159 167 (Pubitemid 30105655)
29. F.R. Nobels, D.J. Kwekkeboom, and W. Coopmans Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones J Clin Endocrinol Metab 82 1997 2622 2628 (Pubitemid 27337883)
30. U.F. Pape, H. Jann, and J. Muller-Nordhorn Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 2008 256 265
31. L. Ramont, H. Thoannes, and A. Volondat Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice Clin Chem Lab Med 43 2005 1215 1217 (Pubitemid 41600673)
32. G. Rindi, G. Kloppel, and H. Alhman TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system Virchows Arch 449 2006 395 401 (Pubitemid 44451313)
33. G. Rindi, G. Kloppel, and A. Couvelard TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system Virchows Arch 451 2007 757 762 (Pubitemid 47497934)
34. A. Scarpa, W. Mantovani, and P. Capelli Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients Mod Pathol 23 2010 824 833
35. A.M. Schmitt, M. Anlauf, and V. Rousson WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors Am J Surg Pathol 31 2007 1677 1682 (Pubitemid 350287565)
36. N. Sunaga, S. Tsuchiya, and K. Minato Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer Oncology 57 1999 143 148 (Pubitemid 29385493)
37. T. Therneau, and P. Grambsch Modeling survival data: extending the Cox model 1st ed. 2000 Springer-Verlag New York
38. W.D. Travis, W. Rush, and D.B. Flieder Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid Am J Surg Pathol 22 1998 934 944 (Pubitemid 28364493)
39. W. Travis, T. Colby, and B. Corrin Histological Typing of Lung and Pleural Tumours. WHO International Histological Classification of Tumours 3rd ed. 1999 Springer Berlin